RecruitingPhase 3NCT07717411

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Sponsor

Hoffmann-La Roche

Enrollment

1,600 participants

Start Date

Nov 30, 2026

Study Type

INTERVENTIONAL

Conditions

Alzheimer s Disease

Summary

This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.

Eligibility

Min Age: 55 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Trontinemab for people with alzheimer s disease. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 55 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTrontinemab

Participants will receive IV trontinemab.

DRUGPlacebo

Participants will receive IV placebo.

Locations(7)

Irvine Center for Clinical Research

Irvine, California, United States

Syrentis Clinical Research

Santa Ana, California, United States

K2 Medical Research, LLC

Maitland, Florida, United States

Basil Clinical

Laurelton, New York, United States

Toronto Memory Program

Toronto, Ontario, Canada

Xuanwu Hospital, Capital Medical University

Beijing, China

Surrey and Borders NHS Foundation Trust

Chertsey, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07717411

Related Trials

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT071696301 location

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

NCT0721472713 locations

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

NCT0759967011 locations

An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

NCT07764146

[18F]NIDF PET Imaging in Tau-related Diseases

NCT073065982 locations